A detailed history of Boston Trust Walden Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Boston Trust Walden Corp holds 14,207 shares of BMY stock, worth $835,087. This represents 0.01% of its overall portfolio holdings.

Number of Shares
14,207
Previous 14,211 0.03%
Holding current value
$835,087
Previous $590,000 24.58%
% of portfolio
0.01%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$39.66 - $51.75 $158 - $207
-4 Reduced 0.03%
14,207 $735,000
Q2 2024

Jul 19, 2024

SELL
$40.25 - $52.99 $4,025 - $5,299
-100 Reduced 0.7%
14,211 $590,000
Q1 2024

Apr 22, 2024

SELL
$47.98 - $54.4 $29,027 - $32,912
-605 Reduced 4.06%
14,311 $776,000
Q4 2023

Jan 24, 2024

SELL
$48.48 - $57.85 $16,580 - $19,784
-342 Reduced 2.24%
14,916 $765,000
Q3 2023

Oct 18, 2023

BUY
$57.89 - $64.73 $44,633 - $49,906
771 Added 5.32%
15,258 $885,000
Q2 2023

Jul 24, 2023

BUY
$63.71 - $70.74 $48,037 - $53,337
754 Added 5.49%
14,487 $926,000
Q1 2023

Apr 19, 2023

SELL
$65.71 - $74.53 $85,685 - $97,187
-1,304 Reduced 8.67%
13,733 $951,000
Q4 2022

Jan 20, 2023

SELL
$68.48 - $81.09 $20,544 - $24,327
-300 Reduced 1.96%
15,037 $0
Q3 2022

Oct 19, 2022

BUY
$0.13 - $76.84 $180 - $106,884
1,391 Added 9.97%
15,337 $1.09 Million
Q2 2022

Jul 22, 2022

BUY
$72.62 - $79.98 $6,826 - $7,518
94 Added 0.68%
13,946 $1.07 Million
Q1 2022

Apr 20, 2022

SELL
$61.48 - $73.72 $202,884 - $243,276
-3,300 Reduced 19.24%
13,852 $1.01 Million
Q4 2021

Jan 21, 2022

SELL
$53.63 - $62.52 $58,993 - $68,772
-1,100 Reduced 6.03%
17,152 $1.07 Million
Q3 2021

Oct 25, 2021

BUY
$59.17 - $69.31 $39,466 - $46,229
667 Added 3.79%
18,252 $1.08 Million
Q2 2021

Jul 22, 2021

SELL
$61.91 - $67.42 $18,573 - $20,226
-300 Reduced 1.68%
17,585 $1.18 Million
Q4 2020

Jan 15, 2021

BUY
$57.74 - $65.43 $6,640 - $7,524
115 Added 0.65%
17,885 $1.11 Million
Q3 2020

Oct 14, 2020

SELL
$57.43 - $63.64 $8,557 - $9,482
-149 Reduced 0.83%
17,770 $1.07 Million
Q2 2020

Jul 23, 2020

SELL
$54.82 - $64.09 $54,820 - $64,090
-1,000 Reduced 5.29%
17,919 $1.05 Million
Q1 2020

Apr 21, 2020

SELL
$46.4 - $67.43 $178,176 - $258,931
-3,840 Reduced 16.87%
18,919 $1.06 Million
Q4 2019

Jan 10, 2020

BUY
$49.21 - $64.19 $296,342 - $386,552
6,022 Added 35.98%
22,759 $1.46 Million
Q1 2019

Apr 16, 2019

SELL
$45.12 - $53.8 $12,227 - $14,579
-271 Reduced 1.59%
16,737 $799,000
Q4 2018

Jan 17, 2019

SELL
$48.76 - $63.23 $50,271 - $65,190
-1,031 Reduced 5.72%
17,008 $884,000
Q3 2018

Oct 23, 2018

SELL
$55.19 - $62.25 $9,327 - $10,520
-169 Reduced 0.93%
18,039 $1.12 Million
Q2 2018

Jul 25, 2018

SELL
$50.53 - $62.98 $58,210 - $72,552
-1,152 Reduced 5.95%
18,208 $1.01 Million
Q1 2018

Apr 13, 2018

SELL
$59.92 - $68.98 $2,336 - $2,690
-39 Reduced 0.2%
19,360 $1.23 Million
Q4 2017

Jan 29, 2018

SELL
$59.94 - $65.35 $55,564 - $60,579
-927 Reduced 4.56%
19,399 $1.19 Million
Q3 2017

Oct 13, 2017

BUY
$55.23 - $63.74 $1.12 Million - $1.3 Million
20,326
20,326 $1.3 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Boston Trust Walden Corp Portfolio

Follow Boston Trust Walden Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Trust Walden Corp, based on Form 13F filings with the SEC.

News

Stay updated on Boston Trust Walden Corp with notifications on news.